0.1490
+0.0020
+(1.38%)
As of 8:11:35 AM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,100.9680
3,100.9680
--
--
--
Cost of Revenue
1,326.7430
1,326.7430
--
--
--
Gross Profit
1,774.2250
1,774.2250
--
--
--
Operating Expense
8,737.9950
8,737.9950
6,871.4890
5,866.3110
2,928.3940
Operating Income
-6,963.7700
-6,963.7700
-6,871.4890
-5,866.3110
-2,928.3940
Net Non Operating Interest Income Expense
71.7970
71.7970
--
--
0.9240
Pretax Income
-6,891.9730
-6,891.9730
-6,871.4890
-5,866.3110
-2,927.4700
Tax Provision
-379.0740
-379.0740
-1,024.9940
-908.6000
-519.0930
Net Income Common Stockholders
-6,512.8990
-6,512.8990
-5,846.4950
-4,957.7110
-2,408.3770
Diluted NI Available to Com Stockholders
-6,512.8990
-6,512.8990
-5,846.4950
-4,957.7110
-2,408.3770
Basic EPS
-0.02
0.02
-0.02
-0.02
-0.01
Diluted EPS
-0.02
0.02
-0.02
-0.02
-0.01
Basic Average Shares
294,912.4040
301,405.9500
287,478.0550
271,046.1790
243,721.3030
Diluted Average Shares
294,912.4040
301,405.9500
287,478.0550
271,046.1790
243,721.3030
Total Operating Income as Reported
-6,963.7700
-6,963.7700
-6,871.4890
-5,866.3110
-2,928.3940
Rent Expense Supplemental
128.2050
128.2050
120.8810
116.1940
116.7140
Total Expenses
10,064.7380
10,064.7380
6,871.4890
5,866.3110
2,928.3940
Net Income from Continuing & Discontinued Operation
-6,512.8990
-6,512.8990
-5,846.4950
-4,957.7110
-2,408.3770
Normalized Income
-6,512.8990
-6,512.8990
-5,846.4950
-4,957.7110
-2,408.3770
Interest Income
71.7970
71.7970
--
--
0.9240
Net Interest Income
71.7970
71.7970
--
--
0.9240
EBIT
-6,963.7700
-6,963.7700
-6,871.4890
-5,866.3110
-2,928.3940
EBITDA
-6,833.4980
-6,833.4980
-6,846.7550
-5,846.5030
-2,903.3860
Reconciled Cost of Revenue
1,326.7430
1,326.7430
--
--
--
Reconciled Depreciation
130.2720
130.2720
24.7340
19.8080
25.0080
Net Income from Continuing Operation Net Minority Interest
-6,512.8990
-6,512.8990
-5,846.4950
-4,957.7110
-2,408.3770
Normalized EBITDA
-6,833.4980
-6,833.4980
-6,846.7550
-5,846.5030
-2,903.3860
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0002
0.0002
12/31/2020 - 2/4/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2HA.F Spero Therapeutics, Inc.
0.7700
0.00%
HQ1.MU Oruka Therapeutics Inc. R
11.20
+3.70%
5CV.MU CureVac NV
3.4940
+1.22%
1AEA.F argenx SE
615.00
+1.68%
BO1.F BioCryst Pharmaceuticals, Inc.
8.88
0.00%
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.3290
-3.52%
07X.BE Annovis Bio Inc
2.4800
+1.45%
600161.SS TIANTAN BIO
20.31
-0.93%
OVIT OncoVista Innovative Therapies, Inc.
0.0002
0.00%
NVAX.MX Novavax, Inc.
160.99
-3.01%